AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27927221
Drug: 45000 IU
RxNorm normalized name: protease 45000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45000 IU weekly for 2 months then 400 IU daily
Trial: 27927221
Drug: 2000 IU
RxNorm normalized name: D 2000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU daily for 3 months then 1000 IU daily
Trial: 25440793
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol (5 mg twice daily)
Trial: 15009069
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol 17beta 0.05 mg and norethisterone acetate 0.125 mg daily
Trial: 11860772
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated hepatitis A vaccine (H2 Strain, 10^7.0 TCID(50)) after booster dose
Trial: 9354540
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous furosemide (0.1 mg x kg(‐1) x h(‐1))
Trial: 9354540
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous furosemide (1 mg/kg bolus every 4 hours)
Trial: 3469164
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg or 300 mg b.i.d.
Trial: 3469164
Drug: Amoxicillin 1
RxNorm normalized name: amoxicillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1 g b.i.d. or t.i.d.
Trial: 30507559
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic injection (1 ml lidocaine of 0.5% for each trigger point)
Trial: 30507559
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic injection + Sham kinesiotaping
Trial: 30507559
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic injection + kinesiotaping
Trial: 30497995
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g acute dose of MSM
Trial: 30497995
Drug: 1 g,
RxNorm normalized name: Sunmark Insulin Syringe 31 g, 1cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g, 3 g, or 6 g daily doses of MSM for 14 days
Trial: 30497995
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g daily dose of MSM
Trial: 26856517
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Swaddling and Breastfeeding
Trial: 19571632
Drug: Aroma essential
RxNorm normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aroma essential oil inhalation
Trial: 19571632
Drug: Carrier oil
RxNorm normalized name: Carrier oil-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrier oil inhalation (placebo)
Trial: 15230446
Drug: Owner education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Owner education (EDU) treatment group
Trial: 9610790
Drug: Beta-Carotene (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-Carotene (30 mg) and Retinyl Palmitate (25,000 units) daily
Trial: 7833223
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 mg once daily)
Trial: 27050908
Drug: Oral glucosamine
RxNorm normalized name: glucosamine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucosamine sulfate (GlcN-S) from T0 to T3, then combined treatment of mud-bath therapy and GlcN-S from T3 to T6.
Trial: 27050908
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of mud-bath therapy and GlcN-S from T0 to T3, then GlcN-S alone from T3 to T6.
Trial: 24351556
Drug: Rosa roxburghii
RxNorm normalized name: ROSA ROXBURGHII FRUIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosa roxburghii tratt preparation (120 ml/d for one month)
Trial: 24351556
Drug: SOD-enriched rosa
RxNorm normalized name: Rosa moschata oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOD-enriched rosa roxburghii tratt juice (120 ml/d for one month)
Trial: 24351556
Drug: Rosa roxburghii
RxNorm normalized name: ROSA ROXBURGHII FRUIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosa roxburghii tratt preparation
Trial: 19166420
Drug: lafutidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 7 days (7LFT group)
Trial: 19166420
Drug: lafutidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 14 days (14LFT group)
Trial: 19166420
Drug: lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 7 days (7LPZ group)
Trial: 19166420
Drug: lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 14 days (14LPZ group)
Trial: 31119383
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (IV-TXA)
Trial: 25957542
Drug: Kaempferia parviflora
RxNorm normalized name: Kaempferia galanga root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaempferia parviflora extract (180 mg capsules once daily for 12 weeks)
Trial: 17709252
Drug: Topical verapamil-nitroglycerin
RxNorm normalized name: nitroglycerin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical verapamil-nitroglycerin solution
Trial: 17709252
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of normothermic organ bath and verapamil-nitroglycerin solution
Trial: 17709252
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antispasmodic treatment)
Trial: 8485065
Drug: xamoterol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoterol (0.2 mg/kg)
Trial: 3524789
Drug: Chemotherapy (6-mercaptopurine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (6-mercaptopurine 70 mg/m2 days 1-14, methotrexate 15 mg/m2 twice weekly days 15-28, reinduction with daunorubicin 35 mg/m2 and vincristine 1 mg/m2 day 29)
Trial: 3524789
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus stanozolol (0.15 mg/kg/day)
Trial: 3524789
Drug: 6-thioguanine (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-thioguanine (70 mg/m2 orally on 4 consecutive days) and cytosine arabinoside (80 mg/m2 subcutaneously day 5 every week)
Trial: 3524789
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus irradiated blast cells treated with neuraminidase
Trial: 31865906
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MBSR and structured exercise
Trial: 25970439
Drug: Calcium-rich dairy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-rich dairy based meal (1352 ± 53 mg calcium)
Trial: 25970439
Drug: Control meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control meal (46 ± 7 mg calcium)
Trial: 23123039
Drug: Bupivacaine (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.5% at 2 cc/h)
Trial: 23123039
Drug: Placebo (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5% saline at 2 cc/h)
Trial: 19002073
Drug: Depth Jump
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depth Jump (DJ) training for 6 weeks, twice weekly
Trial: 19002073
Drug: Countermovement Jump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Countermovement Jump (CMJ) training for 6 weeks, twice weekly
Trial: 16481803
Drug: Methylprednisolone 3
RxNorm normalized name: methylprednisolone 32 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 3 mg.kg‐1 (group 1)
Trial: 16481803
Drug: Lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5 mg.kg‐1 (group 3)
Trial: 16481803
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline physiologic 5 mL (group 2)
Trial: 3519093
Drug: Antacid plus
RxNorm normalized name: Antacid Plus
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antacid plus oxethazaine (8 ml doses as needed for 4 weeks)
Trial: 3519093
Drug: Antacid alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid alone (8 ml doses as needed for 4 weeks)
Trial: 11563588
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan with autologous stem cell transplantation
Trial: 26244520
Drug: Tamsulosin 400 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 400 µg
Trial: 26244520
Drug: Nifedipine 30 mg
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine 30 mg
Trial: 26244520
Drug: Tamsulosin 400 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 400 µg and Nifedipine 30 mg
Trial: 17824846
Drug: CPAP (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP (continuous positive airway pressure) treatment; duration: 1 month; n=12
Trial: 16837619
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg L-selenomethionine per day for 3 months (Group S2)
Trial: 16837619
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg L-selenomethionine per day for 3 months (Group S22)
Trial: 16837619
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg L-selenomethionine per day (Group S212)
Trial: 16837619
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg L-selenomethionine per day (Group S21)
Trial: 16837619
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg L-selenomethionine per day (Group S2)
Trial: 16837619
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg L-selenomethionine per day (Group S222)
Trial: 11482709
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion at 10 mcg/kg/min
Trial: 8097082
Drug: Zalcitabine (2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zalcitabine (2.25 mg/d)
Trial: 8097082
Drug: Zidovudine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (500 to 1200 mg/d)
Trial: 3709638
Drug: cadralazine 15
RxNorm normalized name: cadralazine
DrugBank: Cadralazine (DB13452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cadralazine 15 mg once daily
Trial: 8562470
Drug: chlorthalidone 25
RxNorm normalized name: chlorthalidone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chlorthalidone 25 mg once daily
Trial: 31699944
Drug: ARV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARV therapy using fixed-dose combination (tenofovir, lamivudine, efavirenz)
Trial: 28124288
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy (I-CBT)
Trial: 26613606
Drug: Netupitant/palonosetron 300/0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netupitant/palonosetron 300/0.5 mg
Trial: 26613606
Drug: Palonosetron 0.5
RxNorm normalized name: palonosetron 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.5 mg
Trial: 23799210
Drug: 4-liter split-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-liter split-dose polyethylene glycol (PEG)
Trial: 15350182
Drug: CEE plus
RxNorm normalized name: Ecee Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE plus MPA (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Trial: 8591079
Drug: FAM2 chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAM2 chemotherapy
Trial: 8591079
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no FAM2 chemotherapy)
Trial: 2121487
Drug: Thrombolytic agents
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic agents (streptokinase, t‐PA, APSAC)
Trial: 25995276
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNSs) delivered biweekly to homes
Trial: 21046070
Drug: maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maintenance treatment (initial optimal therapeutic doses continued throughout the study)
Trial: 21046070
Drug: dose-reduction group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose-reduction group (initial optimal therapeutic doses continued for 4 or 26 weeks followed by a 50% dose reduction)
Trial: 19496901
Drug: Thienopyridine administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thienopyridine administration (500 mg ticlopidine or 300 mg clopidogrel)
Trial: 17380456
Drug: Postoperative intra-iliac
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intra-iliac and hepatic arterial infusion chemotherapy (group I)
Trial: 17380456
Drug: Routine vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine vein chemotherapy (group II)
Trial: 15499696
Drug: Gefitinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib monotherapy (250 mg/day and 500 mg/day)
Trial: 23855591
Drug: Standardized physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized physical therapy program
Trial: 9596249
Drug: Acetazolamide 1000
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide 1000 mg i.v.
Trial: 9596249
Drug: Acetazolamide 500
RxNorm normalized name: acetazolamide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 500 mg i.v.
Trial: 31753736
Drug: Mixed amphetamine
RxNorm normalized name: mixed amphetamine salts 5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed amphetamine salts extended-release (MAS-ER) and topiramate
Trial: 18631255
Drug: Once-daily fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily fixed-dose combination tablet of abacavir and lamivudine (ABC/3TC FDC, Kivexa)
Trial: 18631255
Drug: Twice-daily abacavir
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily abacavir and lamivudine (ABC and 3TC)
Trial: 15536660
Drug: Control (non-medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-medicated cream)
Trial: 7677801
Drug: intensive-course 5FU
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intensive-course 5FU plus low-dose leucovorin (5FU 425 mg/m2 plus leucovorin 20 mg/m2 IV push daily for 5 days, courses repeated at 4- to 5-week intervals)
Trial: 7677801
Drug: weekly 5FU
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: weekly 5FU plus high-dose leucovorin (5FU 600 mg/m2 IV push plus leucovorin 500 mg/m2 as a 2-hour infusion weekly for 6 weeks, courses repeated every 8 weeks)
Trial: 7677801
Drug: intensive-course 5FU
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intensive-course 5FU plus low-dose leucovorin
Trial: 7677801
Drug: weekly 5FU
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: weekly 5FU plus high-dose leucovorin
Trial: 2801549
Drug: beta 1‐adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta 1‐adrenergic blockade with optimal dose metoprolol
Trial: 342620
Drug: 200 CCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 CCA units of vaccine
Trial: 342620
Drug: 800 CCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 CCA units of vaccine
Trial: 342624
Drug: Subvirion vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subvirion vaccines
Trial: 342624
Drug: Whole‐virus vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole‐virus vaccines
Trial: 30949708
Drug: Lefamulin (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lefamulin (intravenous and oral administration)
Trial: 26710008
Drug: Submuscular breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submuscular breast augmentation
Trial: 19537523
Drug: Rilmenidine dihydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmenidine dihydrogen phosphate (1.544 mg, equivalent to 1 mg rilmenidine)
Trial: 19537523
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (1.544 mg rilmenidine dihydrogen phosphate)
Trial: 16403735
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g AAs/kg within the first 24 h
Trial: 16403735
Drug: 12 mL
RxNorm normalized name: syringe, disposable, 12 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mL MEF x kg(‐1) x d(‐1) within the first 72 h
Trial: 15569795
Drug: Ivermectin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (200 microg/kg, single dose)
Trial: 15569795
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg/day for 21 days)
Trial: 17440049
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies to beta2-glycoprotein I (abeta2GPI)
Trial: 17440049
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies to prothrombin (aPT)
Trial: 17440049
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies to annexin AV (aAnAV)
Trial: 17440049
Drug: IgM antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM antibodies to protein S
Trial: 17440049
Drug: LA-positive patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA-positive patients with abeta2GPI antibodies
Trial: 17440049
Drug: LA-positive patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA-positive patients with aPT antibodies
Trial: 17440049
Drug: LA-positive patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA-positive patients with IgG abeta2GPI and aAnAV antibodies
Trial: 7532060
Drug: Intensive, short-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive, short-term consolidation (IC) using 1 cycle of intermediate-dose Ara C plus AMSA and 1 cycle of HD-AraC/AMSA
Trial: 7532060
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (refusals) who received no further treatment after early consolidation
Trial: 2122506
Drug: Propranolol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.1 mg.kg‐1)
Trial: 342247
Drug: Piracetam (4,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (4,800 mg daily)
Trial: 30813256
Drug: Tomato pomace
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato pomace extract (1 g)
Trial: 30813256
Drug: Tomato pomace
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato pomace extract (2.5 g)
Trial: 25214979
Drug: Nebulized lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized lidocaine inhalation in addition to routine treatment (groups A2 and B1)
Trial: 25214979
Drug: Nebulized normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized normal saline apart from routine treatment (groups A1 and B2)
Trial: 8985267
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (ligation + sclerotherapy)